SELLAS Life Sciences Group, Inc.
SLS$219M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
7wMarket Overview
Stock performance and key metrics
SLS News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Galinpepimut-S
Acute Myeloid Leukemia
Decitabine
Acute Myeloid Leukemia
pembrolizumab
Acute Myelogenous Leukemia
Galinpepimut-S + Montanide + GM-CSF
Malignant Pleural Mesothelioma
lenalidomide
Multiple Myeloma
SLS009
Hematologic Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Galinpepimut-S | Phase 3 | Acute Myeloid Leukemia | - | - |
Decitabine | Phase 3 | Acute Myeloid Leukemia | - | - |
pembrolizumab | Phase 2 | Acute Myelogenous Leukemia | - | - |
Galinpepimut-S + Montanide + GM-CSF | Phase 2 | Malignant Pleural Mesothelioma | - | - |
lenalidomide | Phase 2 | Multiple Myeloma | - | - |
SLS009 | Phase 2 | Hematologic Malignancies | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply